aBLA Filing Intelligence & Biosimilar Opportunity

Ryzneuta

Efbemalenograstim Alfa-Vuxw

Hematopoietic Growth Factor

Injection

Ryzneuta is an injection that supports white blood cell production in cancer patients undergoing chemotherapy. It helps lower the risk of infection-related complications by boosting the immune system.

Approval Date

16-Nov-23

Data Exclusivity Expiry

16-Nov-27

Market Exclusivity Expiry

16-Nov-35

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

188

2027

225

2028

252

2029

278

2030

292

2031

306

2032

321

Molecule profile

Details & specifications

Molecule

Efbemalenograstim Alfa-Vuxw

Innovator

EVIVE BIOTECHNOLOGY

Dosage Form

Injection

Strength

20 mg/mL

Therapeutic Category

Hematopoietic Growth Factor

Usage

To treat neutropenia

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.